Biotechnology Value Fund L.P.

Biotechnology Value Fund L.P. is a San Francisco-based private investment firm specializing in biotechnology investments. Since its inception in 1993, the firm has focused on building concentrated, long-term investments in small-cap biotechnology companies, performing rigorous diligence and ongoing monitoring of its investments. The firm is committed to working with its portfolio companies as partners in their successes.

The firm's investment strategy includes early-stage venture capital, late-stage venture capital, and post-IPO investments. It has made 167 investments, with 49 lead investments and 29 diversity investments. The firm's portfolio comprises 115 organizations, with notable exits including Kymera Therapeutics, Elevation Oncology, and Relay Therapeutics.

Biotechnology Value Fund's recent investments include Crescent Biopharma, Antares Therapeutics, Verastem Oncology, and Merida Biosciences. The firm has a history of significant stake acquisitions in companies such as Verastem Inc, TScan Therapeutics Inc, and MoonLake Immunotherapeutics, reflecting its strategic focus on biotechnology investments.

The firm's portfolio companies span various sectors within the biotechnology industry, including pharmaceuticals, medical devices, life sciences, therapeutics, biopharma, and clinical trials. This diverse portfolio underscores Biotechnology Value Fund's comprehensive approach to biotechnology investments, aiming to support innovative companies across the biotechnology sector.